LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | HG-5-113-01 | 0.12 | uM | LJP5 | 72 | hr | 1657 | 5005 | 5588 | 0.8959 | 0.8784 |
BT-20 | HG-5-113-01 | 0.37 | uM | LJP5 | 72 | hr | 1657 | 4390 | 5588 | 0.7861 | 0.7411 |
BT-20 | HG-5-113-01 | 1.11 | uM | LJP5 | 72 | hr | 1657 | 3826 | 5588 | 0.6848 | 0.6114 |
BT-20 | HG-5-113-01 | 3.33 | uM | LJP5 | 72 | hr | 1657 | 2727 | 5588 | 0.4883 | 0.3272 |
BT-20 | HG-5-113-01 | 10 | uM | LJP5 | 72 | hr | 1657 | 1376 | 5588 | 0.2464 | -0.1008 |
BT-20 | HG-5-88-01 | 0.04 | uM | LJP6 | 72 | hr | 1657 | 4635 | 5383 | 0.8620 | 0.8330 |
BT-20 | HG-5-88-01 | 0.12 | uM | LJP6 | 72 | hr | 1657 | 5270 | 5383 | 0.9785 | 0.9741 |
BT-20 | HG-5-88-01 | 0.37 | uM | LJP6 | 72 | hr | 1657 | 5293 | 5383 | 0.9836 | 0.9808 |
BT-20 | HG-5-88-01 | 1.11 | uM | LJP6 | 72 | hr | 1657 | 4985 | 5383 | 0.9258 | 0.9107 |
BT-20 | HG-5-88-01 | 3.33 | uM | LJP6 | 72 | hr | 1657 | 4472 | 5383 | 0.8310 | 0.7936 |
BT-20 | HG-5-88-01 | 10 | uM | LJP6 | 72 | hr | 1657 | 3006 | 5383 | 0.5586 | 0.4192 |
BT-20 | HG-6-64-01 | 0.04 | uM | LJP6 | 72 | hr | 1657 | 5824 | 5383 | 1.0838 | 1.0974 |
BT-20 | HG-6-64-01 | 0.12 | uM | LJP6 | 72 | hr | 1657 | 5436 | 5383 | 1.0111 | 1.0135 |
BT-20 | HG-6-64-01 | 0.37 | uM | LJP6 | 72 | hr | 1657 | 4625 | 5383 | 0.8589 | 0.8282 |
BT-20 | HG-6-64-01 | 1.11 | uM | LJP6 | 72 | hr | 1657 | 3977 | 5383 | 0.7392 | 0.6742 |
BT-20 | HG-6-64-01 | 3.33 | uM | LJP6 | 72 | hr | 1657 | 2994 | 5383 | 0.5567 | 0.4163 |
BT-20 | HG-6-64-01 | 10 | uM | LJP6 | 72 | hr | 1657 | 904 | 5383 | 0.1679 | -0.3007 |
BT-20 | Neratinib | 0.04 | uM | LJP5 | 72 | hr | 1657 | 4519 | 5588 | 0.8091 | 0.7717 |
BT-20 | Neratinib | 0.12 | uM | LJP5 | 72 | hr | 1657 | 4407 | 5588 | 0.7888 | 0.7469 |
BT-20 | Neratinib | 0.37 | uM | LJP5 | 72 | hr | 1657 | 4244 | 5588 | 0.7597 | 0.7095 |
BT-20 | Neratinib | 1.11 | uM | LJP5 | 72 | hr | 1657 | 3794 | 5588 | 0.6788 | 0.6028 |
BT-20 | Neratinib | 3.33 | uM | LJP5 | 72 | hr | 1657 | 3315 | 5588 | 0.5932 | 0.4846 |
BT-20 | Neratinib | 10 | uM | LJP5 | 72 | hr | 1657 | 2883 | 5588 | 0.5159 | 0.3701 |
BT-20 | JW-7-24-1 | 0.04 | uM | LJP6 | 72 | hr | 1657 | 4770 | 5383 | 0.8867 | 0.8631 |
BT-20 | JW-7-24-1 | 0.12 | uM | LJP6 | 72 | hr | 1657 | 5194 | 5383 | 0.9643 | 0.9570 |